Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Acquired in-process research and development expenses by Quarter
Acquired in-process research and development (IPR&D) expenses ($M) ($M)
Gilead Sciences Acquired in-process research and development expenses: $11,183M in Q2 2026, up 18,232.8% from a year earlier. That is the highest of the 29 quarters on record here.
Where the Q2 2026 figure comes from
“|| Acquired IPR&D expenses | $ | 11,183 | $ | 61 | NM | $ | 11,290 | $ | 315 | NM”
Source: Form 8-K (exhibit991earningspressrel.htm, filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Consolidated Statements of Operations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up acquired in-process research and development expenses
Cite this data
StockData. (2026). Gilead Sciences Acquired in-process research and development expenses ($M), quarterly Q2 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/iprd-acquired-exp
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.